# EPRX catalysts: EUPRAXIA PHARMACEUTICALS INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/eprx/catalysts

> EUPRAXIA PHARMACEUTICALS INC. (EPRX) has 1 upcoming catalyst. The next is the EP-104 interim data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | EUPRAXIA PHARMACEUTICALS INC. |
| Ticker | EPRX (Nasdaq) |
| SEC CIK | 1581178 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/eprx |

## Cash runway

Cash $80.6M as of 2025-12-31; quarterly burn $7.1M; about 33.8 months of runway at that rate (XBRL company facts, accession 0001193125-26-104765).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| June 26, 2023 | [EP-104 topline data readout](https://sec-api.dev/pdufa/ep-104) | EPRX |  | completed, positive | "Top-line data readout was positive, and was announced on June 26, 2023." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm)) |
| July 7, 2025 | [EP-104 trial start](https://sec-api.dev/pdufa/ep-104) | EPRX |  | completed | "The first patient was dosed in the randomized dose optimization portion of the study on July 7, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm)) |
| July 8, 2025 | [EUPRAXIA PHARMACEUTICALS INC. trial start](https://sec-api.dev/companies/eprx/catalysts) | EPRX |  | completed | "VICTORIA, British Columbia, July 08, 2025 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today announced the first patient dosed in the Phase 2b randomized, placebo-controlled portion of the RESOLVE clinical trial evaluating EP-104GI, an investigational treatment for eosinophilic esophagitis ("EoE")." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000117184325004357/exh_991.htm)) |
| August 12, 2025 | [EP-104 trial start](https://sec-api.dev/pdufa/ep-104) | EPRX |  | completed | "Announced first patient dosed in the Phase 2b placebo-controlled portion of the" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312525179135/d54647dex993.htm)) |
| Q3 2026 | [Fluticasone topline data readout](https://sec-api.dev/pdufa/fluticasone) | EPRX |  | scheduled | "The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000117184325007294/exh_991.htm)) |
| Q3 2026 | [EUPRAXIA PHARMACEUTICALS INC. topline data readout](https://sec-api.dev/companies/eprx/catalysts) | EPRX |  | scheduled | "The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q3 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000117184326001612/exh_991.htm)) |
| Q3 2026 | [EP-104 topline data readout](https://sec-api.dev/pdufa/ep-104) | EPRX |  | scheduled | "Enrollment continues in Phase 2b portion of the RESOLVE Trial, with topline data expected by Q3 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312525264619/d35661dex993.htm)) |
| Q4 2026 | [EUPRAXIA PHARMACEUTICALS INC. topline data readout](https://sec-api.dev/companies/eprx/catalysts) | EPRX |  | scheduled | "The top-line data from the Phase 2b part of the RESOLVE trial is expected in Q4 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000117184326003051/exh_991.htm)) |
| Dec 2026 | [EP-104 interim data readout](https://sec-api.dev/pdufa/ep-104) | EPRX |  | scheduled | "In December 2026, the Company expects to release interim data from the Phase 2b portion of the RESOLVE study." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1581178/000119312526455405/d98561dex992.htm)) |

## Drugs

- [EP-104](https://sec-api.dev/pdufa/ep-104): 
- [Fluticasone](https://sec-api.dev/pdufa/fluticasone): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/eprx/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "EPRX catalysts: EUPRAXIA PHARMACEUTICALS INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/eprx/catalysts

```bibtex
@misc{secapidev_companies_eprx_catalysts_20261116,
  title        = {EPRX catalysts: EUPRAXIA PHARMACEUTICALS INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/eprx/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_eprx_catalysts_20261116","title":"EPRX catalysts: EUPRAXIA PHARMACEUTICALS INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/eprx/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
